Tuesday, February 18, 2020

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strikes Licensing Deal with Cannadips CBD


British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently entered a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD. An article discussing the company reads, “The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption technology with options to expand the license to Europe, Mexico, and Canada and to renew the license for an additional five years (http://ibn.fm/8hoPO). . . . ‘This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination. We are excited to be developing a category of products with best-in-class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine,’ Lexaria board member Brian Quigley, who is also an adviser to The Boldt Runners Corporation (Cannadips), stated in a news release.”

To view the full article, visit http://ibn.fm/cxOZx

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual-property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: